ARDX Ardelyx Inc.

0  0%
Previous Close 4.4
Open 4.4
Price To Book 2.05
Market Cap 264455699
Shares 60,103,568
Volume 146,791
Short Ratio 0.93
Av. Daily Volume 835,807

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Free Technical Reports on Array BioPharma and Three Additional Biotech Equities
  2. Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications
  3. Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
  4. Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row
  5. Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing
  6. Ardelyx Announces Pricing of Public Offering of Common Stock
  7. Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
  8. Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
  9. Ardelyx Announces Proposed Public Offering of Common Stock
  10. Ardelyx: 1Q Earnings Snapshot
  11. Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
  12. Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
  13. Ardelyx posts 4Q profit
  14. Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
  15. Ardelyx Announces Departure of Chief Scientific Officer
  16. Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
  17. Best NasdaqGM Growth Stocks
  18. 5 Great Breakout Stocks Offering Superlative Returns